📰 Webcast Only News
Webcast Only News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Webcast Only. Real-time updates on events, politics, business and more.
March 26, 2024
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile…
October 26, 2023
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 ...
July 27, 2023
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company…
May 8, 2023
08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for ...
October 18, 2022
SAN DIEGO and TORONTO, Oct. 18, 2022 -- Aptose Biosciences Inc. , a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic... | October 18, 2022
July 19, 2022
SAN DIEGO and TORONTO, July 19, 2022 -- Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic...